To The Moon

💬 Join the discussion: Vote in our poll below and share your take in the comments — every useful comment earns Tiger Coins! 🎁

Ten U.S. stocks with market caps above $10 billion are trading at fresh all-time highs as of September 1, 2026. The top 10 are dominated by energy — spanning independent refiners ( $Marathon Petroleum(MPC)$, $Valero(VLO)$, $Phillips 66(PSX)$, $HF Sinclair Corporation(DINO)$) and LNG export infrastructure ( $Cheniere Energy Partners LP(CQP)$) — alongside one cybersecurity leader ( $CrowdStrike Holdings, Inc.(CRWD)$), one South Korean banking group ( $KB Financial Group Inc(KB)$), one clinical-stage biopharma pinned to a pending cash acquisition ( $Apogee Therapeutics(APGE)$), one recently spun-off global consumer staples name ( $Magnum Ice Cream Co BV/The(MICC)$), and one crypto-treasury-linked preferred security ( $BITMINE IMMERSION TECHNOLOGIES INC 9.5 SER A CUM PREF STK(BMNP)$). This concentration points to a refining margin supercycle driven by Middle East-linked crude and product supply disruptions (crack spreads at multi-year highs, EPS surprises above 100% across the refiner cohort), a reacceleration in AI-driven cybersecurity demand as enterprises secure both human and agentic workloads, and pockets of idiosyncratic strength — Korean bank capital-return programs, biotech M&A pricing, and post-spinoff consumer execution — rounding out the market's current momentum drivers.

The top 10 tickers leading this cohort - $CrowdStrike Holdings, Inc.(CRWD)$, $Marathon Petroleum(MPC)$, $Valero(VLO)$, $Phillips 66(PSX)$, $KB Financial Group Inc(KB)$, $Cheniere Energy Partners LP(CQP)$, $HF Sinclair Corporation(DINO)$, $BITMINE IMMERSION TECHNOLOGIES INC 9.5 SER A CUM PREF STK(BMNP)$, $Magnum Ice Cream Co BV/The(MICC)$, $Apogee Therapeutics(APGE)$

🧭 Key Market Drivers

• Refining supercycle on tight global supply: Middle East-linked disruptions to crude and product flows have pushed U.S. crack spreads to multi-year highs, driving record quarters for $Marathon Petroleum(MPC)$, $Valero(VLO)$, $Phillips 66(PSX)$ and $HF Sinclair Corporation(DINO)$, with margin capture rates above 100% and EPS surprises of 100%+ across the group.

• AI reaccelerates cybersecurity demand: $CrowdStrike Holdings, Inc.(CRWD)$ posted its best quarter in company history as AI agents themselves become new Falcon customers, triggering an 18%+ single-day rally and a wave of double-digit price-target hikes from Wall Street.

• M&A repricing smaller caps: $Apogee Therapeutics(APGE)$ is trading flat against its all-time high because it is pinned to $AbbVie(ABBV)$'s pending $135.11/share cash acquisition, while reported (and later denied/collapsed) PSX-MPC merger talks kept refiners in deal-speculation headlines.

• Global consumer and financial re-ratings: $KB Financial Group Inc(KB)$ Financial's record Korean banking profits and $Magnum Ice Cream Co BV/The(MICC)$'s steady post-spinoff execution show non-U.S. and recently spun-off names also grinding to new highs alongside the domestic energy and tech leaders.

1. $CrowdStrike Holdings, Inc.(CRWD)$

• Core Business:
  Cloud-native cybersecurity platform (Falcon) covering endpoint, cloud, identity, and data protection, increasingly extending into AI-agent security.

• Latest Developments:
  CrowdStrike reports fiscal Q2 2027 results on August 26, 2026, showing record net new ARR of $332.8 million and framing AI agents as an emerging customer base ("AIDR"); shares surged as much as 18% the next day, and the company heads into its Fal.Con 2026 conference (Aug 31–Sep 3, 2026) with a record Q3 pipeline.

• Latest Earnings Highlights (Q2 FY2027, reported Aug 26, 2026):
  Revenue of $1.47 billion, up 26% YoY, beating the $1.44 billion consensus; adjusted EPS of $0.31 vs. $0.29 expected; ending ARR grew 25% to $5.84 billion; full-year revenue guidance raised to $5.99–$6.01 billion.

• Price Target Outlook:
  Morgan Stanley raised its target to $238 from $227 (Overweight); Raymond James lifted its target to $240 from $188; Scotiabank raised to $250 from $227; RBC Capital raised to $260 from $256.

2. $Marathon Petroleum(MPC)$

• Core Business:
  Independent refiner and midstream operator running one of the largest U.S. refining systems, with fuel marketing and a controlling stake in MPLX.

• Latest Developments:
  MPLX raised its 2026 growth-capital outlook by $500 million to $2.9 billion on Aug 4, 2026, targeting Permian and Marcellus gas/NGL infrastructure to support 12.5% annual distribution growth in 2026–2027; MPC and PSX were reported to have held—and subsequently abandoned—merger talks earlier in 2026.

• Q2 2026 Financial Highlights (reported Aug 4, 2026):
  Net income attributable to MPC of $5.1 billion ($17.73 diluted EPS) vs. $1.2 billion a year earlier, beating the ~$14 consensus; adjusted EBITDA of $8.5 billion with 112% refining margin capture; R&M margin of $36.33/bbl vs. $17.58 a year ago; $2.8 billion returned to shareholders in the quarter.

• Price Target Outlook:
  Barclays raised its target to $321 from $289 (Aug 6, 2026); Wells Fargo raised to $359 from $344 (Overweight); TD Cowen lifted its target to $375 post-earnings.

3. $Valero(VLO)$

• Core Business:
  Multinational refiner operating 14 petroleum refineries plus renewable diesel (via Diamond Green Diesel) and ethanol production.

• Latest Developments:
  Shares traded near a 52-week high of $353 in late August 2026 as Middle East-linked crude-supply disruptions extended crack-spread strength into the third quarter; the company continued an active buyback program alongside its regular dividend.

• Q2 2026 Financial Highlights (reported Jul 30, 2026):
  Adjusted EPS of $12.54, beating the $10.22 estimate; revenue of $44.48 billion vs. $39.45 billion expected; refining operating income improved sharply on higher crack spreads and utilization.

• Price Target Outlook:
  Jefferies raised its target to $401 from $312 (Aug 24, 2026, Neutral); UBS lifted its target to $355 from $280; TD Cowen raised to $350 from $338.

4. $Phillips 66(PSX)$

• Core Business:
  Integrated downstream company spanning refining, midstream (including CPChem petrochemicals stake), chemicals, and marketing/specialties.

• Latest Developments:
  Phillips 66, Kinder Morgan, and HF Sinclair finalized a joint-venture agreement and took a final investment decision on the $5 billion Western Gateway Pipeline system; management guided Q3 2026 refinery utilization to the mid-90% range.

• Q2 2026 Financial Highlights (reported Aug 5, 2026):
  Adjusted earnings of $3.8 billion, or $9.41 per share, the company's strongest quarterly profit since 2022; net debt reduced to $16.5 billion, ahead of its sub-$17 billion target; $887 million returned to shareholders via dividends and buybacks.

• Price Target Outlook:
  TD Cowen raised its target to $255 from $240 (Buy); Mizuho raised to $220 from $212 (Outperform, Aug 11, 2026); Citi, Wells Fargo and Barclays also lifted targets in the days following earnings.

5. $KB Financial Group Inc(KB)$

• Core Business:
  South Korea's largest financial holding company, spanning Kookmin Bank retail/corporate banking, KB Securities, insurance, and asset management.

• Latest Developments:
  KB Financial unveiled its H1 2026 results on July 23, 2026, disclosing a board-approved KRW 700 billion buyback-and-cancellation program and plans to return excess capital above a 13.5% CET1 ratio to shareholders by year-end, targeting roughly KRW 3.7 trillion in total 2026 shareholder returns.

• Q2 2026 Financial Highlights:
  H1 2026 net profit of KRW 3.88 trillion, up 13.1% YoY; Q2 EPS of $3.79 vs. $3.21 estimate; ROE improved to 14.09%; CET1 ratio rose to 13.74%; total operating income topped KRW 10 trillion for the first time, aided by 33.3% YoY growth in non-interest income.

• Price Target Outlook:
  Covered by roughly 40 analysts with a broadly positive consensus; recent commentary has framed 2026 ROE guidance of above 11% (medium-term target ~13%) as supportive of continued re-rating in Korean bank equities.

6. $Cheniere Energy Partners LP(CQP)$

• Core Business:
  Owns and operates the Sabine Pass LNG terminal, one of the largest liquefaction/export facilities in the U.S., generating fee-based cash flows from long-term LNG contracts.

• Latest Developments:
  Reported Q2 2026 results on August 6, 2026, with volumes and non-cash derivative gains lifting income sharply; distribution guidance was maintained at $3.10–$3.40 per unit for the year.

• Q2 2026 Financial Highlights:
  Adjusted EBITDA rose 35% YoY to $983 million; LNG volumes loaded increased 13% to 396 TBtu; results included roughly $526 million of non-cash gains on commodity derivatives tied to long-term contracts.

• Price Target Outlook:
  Consensus rating is mixed-to-cautious (Neutral-leaning) despite the shares trading near record highs; the average analyst price target sits in the high-$50s to $60s, below the current share price, reflecting concerns valuation has outrun fundamentals.

7. $HF Sinclair Corporation(DINO)$

• Core Business:
  Independent refiner and marketer with Refining, Lubricants & Specialty Products, Renewables, and Midstream segments across the U.S. Mid-Continent, Southwest, and Pacific Northwest.

• Latest Developments:
  Reported Q2 2026 results on July 28, 2026, with management outlining a strategic spin-off plan alongside continued leadership transition (interim CEO Franklin Myers); the company returned capital to shareholders via dividends and buybacks during the quarter.

• Q2 2026 Financial Highlights:
  Adjusted EPS of $5.31 vs. $4.46 consensus; revenue of $10.39 billion, beating estimates by roughly 38.5%; net income attributable to HF Sinclair of $892 million vs. $208 million a year earlier.

• Price Target Outlook:
  Goldman Sachs raised its target to $114 from $109 (Jul 29, 2026); UBS raised to $105 from $80; TD Cowen raised to $100 from $90; Barclays raised to $86 from $81.

8. $BITMINE IMMERSION TECHNOLOGIES INC 9.5 SER A CUM PREF STK(BMNP)$

• Core Business:
  Fixed-income-style preferred security issued by BitMine Immersion Technologies (NYSE: BMNR), a company focused on accumulating Ethereum and Bitcoin treasury holdings alongside mining operations in Trinidad and Texas.

• Latest Developments:
  Parent company BMNR has continued disclosing regular increases in its Ethereum treasury, reporting holdings of roughly 5.8 million ETH as of August 16, 2026, alongside total crypto-and-cash holdings near $11.8 billion; the board has also declared a recurring schedule of cash dividends on the preferred shares through the end of 2026.

• Latest Financial Highlights:
  As a preferred instrument, BMNP does not report standalone operating results; its value tracks the parent's balance-sheet strength (crypto holdings) and its fixed 9.5% dividend rate rather than a P/E or EPS metric.

• Price Target Outlook:
  No formal sell-side rating or price target is maintained on the preferred shares; the security trades near its post-issuance high, reflecting steady income demand rather than analyst-driven re-rating.

9. $Magnum Ice Cream Co BV/The(MICC)$

• Core Business:
  Global ice cream manufacturer spun off from Unilever in 2025, owning the Magnum, Ben & Jerry's, Cornetto and Wall's brands across the Americas, Asia, and META regions.

• Latest Developments:
  Reported H1 2026 results on July 30, 2026, showing organic sales growth that outpaced consensus but decelerated from the prior-year comparable period; the stock has more than rebounded from a 2026 low near €11 to fresh all-time highs by late August.

• H1 2026 Financial Highlights:
  Organic sales growth of 4.7% for H1 (4.9% in Q2 alone), with margin improvement and innovation-led gains cited across all regions and brands.

• Price Target Outlook:
  Morgan Stanley raised its target to €17.50 from €15.60 (Overweight); Jefferies raised its target to €13.50 from €13.00 (Hold).

10. $Apogee Therapeutics(APGE)$

• Core Business:
  Clinical-stage biotechnology company developing optimized biologics for inflammatory and immunology diseases, led by zumilokibart (APG777) in atopic dermatitis.

• Latest Developments:
  Shareholders approved AbbVie's acquisition of Apogee on August 11, 2026, at $135.11 per share in cash, following May 2026 positive Phase 2 APEX Part B data and a $1.3 billion financing collaboration with Blackstone Life Sciences to fund Phase 3 development.

• Latest Earnings Highlights (Q2 2026, reported Aug 10, 2026):
  Results were reported alongside pipeline updates and the pending AbbVie deal; the quarter's news flow was dominated by the acquisition announcement rather than standalone operating metrics, consistent with a clinical-stage, pre-revenue biotech.

• Price Target Outlook:
  Multiple analysts (Truist, Mizuho, UBS, Deutsche Bank, Stifel) moved price targets to $135–$135.11 and downgraded ratings to Hold/Neutral following the AbbVie deal announcement, effectively capping the stock at deal value — consistent with its 0.00% distance from all-time highs.

🐯 Your Turn: Which New-High Trade Still Has Room to Run?

📊 Quick Poll: With 10 U.S. stocks hitting fresh all-time highs, which theme do you think has the most upside left from here?

A) Refining Supercycle — MPC, VLO, PSX, DINO

B) AI-Driven Cybersecurity — CRWD

C) Global Consumer & Financial Re-ratings — KB, MICC

D) None — I'd wait for a pullback before chasing new highs

Vote below, then tell us:

• Which ONE stock from the top 10 would you be most willing to buy at today's level — and why?

• Do you think the refining rally is still being driven by genuine supply tightness (Middle East disruptions, crack spreads), or has the move started to run ahead of the fundamentals?

• Bonus: Which ticker do you think will be the first to set another fresh all-time high over the next 30 days?

🎁 Every useful and thoughtful comment will receive Tiger Coins!

Let's see whether Tiger traders are still chasing the breakout — or waiting for the dip. 🐯📈